CONTENTS

Statement of—	Pa
Adriani, Dr. John, Charity Hospital, New Orleans, La- Bryan, Dr. Paul, Director, Bureau of Medicine Task Force, Food and Drug Administration; accompanied Dr. Herbert L. Ley, Jr.,	508
Commissioner FDA	513
Commissioner, FDA. Eichenwald, Dr. Heinz F., William Buchanan professor and chairman, Deposition of Podictivity of Torsor Southwestern	010
Department of Pediatrics, University of Texas Southwestern Medical School, Dallas, Tex	F01
Goodrich, William W., counsel, Office of General Counsel, U.S. Department of Health, Education, and Welfare; accompanied Dr.	501 513
Herbert L. Ley, Jr., Commissioner, FDA. Hewitt, Dr. William L., professor of medicine, University of California School of Medicine, Los Angeles, Calif Jennings, Dr. John, Acting Director, Bureau of Medicine, Food and	504
Drug Administration: accompanied Dr. Herbert L. Lev. Jr.	
Commissioner, FDA Kirby, Dr. William M. M., professor of medicine, University of	513
Washington School of Medicine Scottle Week	500
Washington School of Medicine, Seattle, Wash. Kunin, Dr. Calvin M., chairman, Department of Preventive Medicine,	500
University of Virginia, Charlottesville, Va	502
Lev. Dr. Herbert L., Jr., Commissioner of Food and Drugs, Consumer	-
Protection and Environmental Health Service, Public Health Serv-	
ice, U.S. Department of Health, Education, and Welfare; accom-	
panied by William W. Goodrich, Counsel, Office of General Counsel;	
Dr. John Jennings, Acting Director, Bureau of Medicine, Food and Drug Administration; and Dr. Paul Bryan, Director, Bureau	
of Medicine Task Force, Food and Drug Administration	513
Wise, Robert I., M.D., Ph. D., professor of medicine and chairman.	75
Department of Medicine, Jefferson Medical College, 1025 Walnut	
Street, Philadelphia, Pa	507
EXHIBITS	
Letter to physicians from J. C. Gauntlett, vice president and director, the Upjohn Co., re drug Panalba	506
Chart: Etiologic agents of infectious diseases	508
Chart: Therapeutic anti-infective agents	508
Department, the Upjohn Co., from William R. Merchant, M.D.	
Department, the Upjohn Co., from William R. Merchant, M.D., Director, Veterans' Administration Hospital, Madison, Wis., with enclosures	513
Memorandum, dated April 29, 1969, to Dr. Paul A. Bryan, from Dr.	
Max B. McQueen, re Panalba review of records obtained by FDA	440
inspector, Roy D. Sanberg, from the Upjohn Co. files on March 7, 1969	514
Food and Drug Administration/Bureau of Medicine report on number of patients adversely affected by the use of Panalba	516
Announcement on new labeling requirement of drug novobiocin by HEW,	ort
published in the Federal Register, May 2, 1969	516
New labeling requirement of drug novobiocin, dated May 19, 1969	517
hysicians' letters to Commissioner Ley on Panalba and Mysteclin-F	-
with geographical breakdown	518